DSpace Repository
Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in turkey
Login
English
Türkçe
DSpace Home
→
Araştırma Çıktıları | Scopus
→
Araştırma Çıktıları | Scopus İndeksli Yayınlar Koleksiyonu
→
View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in turkey
Soyer, N.
;
Ali, R.
;
Turgut, M.
;
Haznedaroğlu, İ.C.
;
Yilmaz, F.
;
Aydoğdu, İ.
;
Pir, A.
;
Karakuş, V.
;
Özgür, G.
;
Kiş, C.
;
Ceran, F.
;
Ilhan, G.
;
Özkan, M.
;
Aslaner, M.
;
Ince, İ.
;
Yavaşoğlu, İ.
;
Gediz, F.
;
Sönmez, M.
;
Güvenç, B.
;
Özet, G.
;
Kaya, E.
;
Vural, F.
;
Şahin, F.
;
Töbü, M.
;
Durusoy, R.
;
Saydam, G.
URI:
http://hdl.handle.net/11616/71798
Date:
2021
Abstract:
Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. © TÜBİTAK.
Show full item record
Files in this item
Files
Size
Format
View
There are no files associated with this item.
This item appears in the following Collection(s)
Araştırma Çıktıları | Scopus İndeksli Yayınlar Koleksiyonu
[10117]
Search DSpace
Search DSpace
This Collection
Advanced Search
Browse
All of DSpace
Communities & Collections
By Issue Date
Authors
Titles
Subjects
By Submit Date
By Type
Language
Publisher
Department
Rights
This Collection
By Issue Date
Authors
Titles
Subjects
By Submit Date
By Type
Language
Publisher
Department
Rights
My Account
Login
Register